Use of Monoclonal Antibodies against COVID-19
In addition to the neutralising monoclonal antibodies Bamlanivimab (Eli Lilly) and Casirivimab/Imdevimab (Roche/Regeneron), which are already available in Germany, another monoclonal antibody from the U.S. pharmaceutical company Eli Lilly, Etesevimab, is expected to be available in Germany in June 2021 for use in combination therapy together with Bamlanivimab.
The medicines are currently in clinical trials and have not yet been authorised. The antibody Etesevimab is to be used exclusively in combination with the antibody Bamlanivimab for the treatment of confirmed COVID-19 disease in patients aged 12 years or older, weighing at least 40 kg and who have risk factors for severe disease progression.
Bamlanivimab may continue to be used as monotherapy, taking into account the epidemiologic situation and the individual patient.
Reference is made to the current information sheets for healthcare professionals and patients on the various therapeutic options.